

## Zydus and Bayer announce continuity of their successful Joint Venture

Mumbai, June 21, 2021

- *The joint venture between the two organisations will be extended for 3 years*
- *Bayer Zydus Pharma will continue to operate in therapies including cardiology, diabetes, women's health, ophthalmology and oncology, with new products in the pipeline*
- *At a time when healthcare is most needed, this JV will continue to focus on innovation-led, patient-centric offerings and digital health solutions*

Bayer (South East Asia) Pte Ltd and Cadila Healthcare Limited today announced the extension of their Joint Venture by three years from June 2021. The companies first entered into an agreement on January 28, 2011 to set up the Joint Venture - Bayer Zydus Pharma Private Limited for the sales and marketing of pharmaceutical products in India, with headquarters in Mumbai.

Over the last ten years, Bayer Zydus Pharma has been a successful partnership combining Bayer's scientific expertise and commercialization of novel products backed by Cadila Healthcare's strong India presence. The Joint venture company focused on addressing the unmet healthcare needs of patients in India by providing best-in-class innovative health solutions. During the term of the joint venture, the company also launched some of Bayer's global innovative assets like Xarelto<sup>®</sup>, Eylea<sup>™</sup> and Visanne<sup>®</sup> in India. Bayer Zydus Pharma will continue to operate in core therapies including cardiovascular diseases, diabetes, women's health, ophthalmology and oncology, with new products in the pipeline. Key products in the company's pharmaceutical portfolio include Xarelto<sup>®</sup>, Glucobay<sup>®</sup>, Eylea<sup>™</sup>, Yaz<sup>®</sup>, Mirena<sup>®</sup> and Visanne<sup>®</sup> amongst others. Through strategic and time-honoured alliances with local partners, Bayer Zydus Pharma will continue to offer new-generation therapies to address the nation's prevailing and emerging health concerns.

Mr. Manoj Saxena, Managing Director, Bayer Zydus Pharma, said, "The Joint Venture with our trusted partner Zydus Cadila has been successful over the last decade in driving scalable reach of our health solutions to patients across the country. We endeavour to carry this momentum forward, harnessing the benefits of our partnership towards delivering innovation-led, patient-centric offerings and digital health tools in India. By sustaining the gains we have made over the years, we aim to fulfill unmet patient needs, strengthen the Indian healthcare ecosystem and translate our vision of 'Health for All, Hunger for None' into reality."

Speaking on the development, Managing Director of Cadila Healthcare Ltd., Dr. Sharvil Patel said, "We have always believed in the power of collaboration and working with partners to create win-win alliances which unlock value for patients and the healthcare system at large. The spirit of partnership in this joint venture has all been about channeling the core strengths of both Zydus and Bayer for the benefit of the patients. By maximizing the reach, enabling access to innovative products for the patients and leveraging expertise for better health outcomes, the JV has set a benchmark. Moving ahead, we see the efforts intensifying as we address a common goal of contributing to a robust and sustainable healthcare system in India."

**About Zydus**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

**About Bayer**

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to [www.bayer.com](http://www.bayer.com).

**Media Contact**

Sophia Gonsalves  
Communications, Bayer Zydus Pharma Ltd.  
E-mail: [sophia.gonsalves@bayer.com](mailto:sophia.gonsalves@bayer.com)

**Media Contact**

Sujatha Rajesh  
Corporate Communications  
Zydus Cadila  
[Sujatha.rajesh@zyduscadila.com](mailto:Sujatha.rajesh@zyduscadila.com)

\*\*\*